These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 16034467)
21. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis. Boruchov AM Semin Hematol; 2009 Jan; 46(1 Suppl 2):S37-43. PubMed ID: 19245933 [TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485 [TBL] [Abstract][Full Text] [Related]
23. Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow. Wang JC; Hashmi G Leuk Res; 2003 Jan; 27(1):13-7. PubMed ID: 12479847 [TBL] [Abstract][Full Text] [Related]
24. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Ichikawa N; Ishida F; Shimodaira S; Tahara T; Kato T; Kitano K Thromb Haemost; 1996 Aug; 76(2):156-60. PubMed ID: 8865522 [TBL] [Abstract][Full Text] [Related]
25. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes]. Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866 [TBL] [Abstract][Full Text] [Related]
26. Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. Wang W; Matsuo T; Yoshida S; Mori H; Miyazaki Y; Kuriyama K; Tomonaga M Leukemia; 2000 Oct; 14(10):1751-6. PubMed ID: 11021750 [TBL] [Abstract][Full Text] [Related]
27. An autopsy case of myelodysplastic syndrome (MDS): diagnostic problems between MDS and the other haematopoietic disorders including acute myelofibrosis. Hayashi Y; Tange T; Chi LC; Ishida T; Kitamura T; Kitamura K; Urano Y Nihon Ketsueki Gakkai Zasshi; 1989 Feb; 52(1):49-54. PubMed ID: 2741651 [TBL] [Abstract][Full Text] [Related]
28. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). Wang JC; Hemavathy K; Charles W; Zhang H; Dua PK; Novetsky AD; Chang T; Wong C; Jabara M Exp Hematol; 2004 Oct; 32(10):905-10. PubMed ID: 15504545 [TBL] [Abstract][Full Text] [Related]
30. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Siitonen T; Savolainen ER; Koistinen P Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174 [TBL] [Abstract][Full Text] [Related]
31. Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis. Bock O; Neusch M; Büsche G; Mengel M; Kreipe H Eur J Haematol; 2004 Apr; 72(4):239-44. PubMed ID: 15089760 [TBL] [Abstract][Full Text] [Related]
32. Thrombopoietin and myelodysplastic syndromes. Ogata K; Tamura H Int J Hematol; 2000 Aug; 72(2):173-7. PubMed ID: 11039665 [TBL] [Abstract][Full Text] [Related]
33. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Komura E; Tonetti C; Penard-Lacronique V; Chagraoui H; Lacout C; Lecouédic JP; Rameau P; Debili N; Vainchenker W; Giraudier S Cancer Res; 2005 Apr; 65(8):3281-9. PubMed ID: 15833861 [TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-beta overexpression in cutaneous extramedullary hematopoiesis of a patient with myelodysplastic syndrome associated with myelofibrosis. Kawakami T; Kimura S; Kato M; Mizoguchi M; Soma Y J Am Acad Dermatol; 2008 Apr; 58(4):703-6. PubMed ID: 18342720 [TBL] [Abstract][Full Text] [Related]
35. In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF). Faulhaber M; Wörmann B; Ganser A; Verbeek W Ann Hematol; 2002 Dec; 81(12):695-700. PubMed ID: 12483365 [TBL] [Abstract][Full Text] [Related]
36. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875 [TBL] [Abstract][Full Text] [Related]
37. Suspects in the tale of lupus-associated thrombocytopenia. Ziakas PD; Routsias JG; Giannouli S; Tasidou A; Tzioufas AG; Voulgarelis M Clin Exp Immunol; 2006 Jul; 145(1):71-80. PubMed ID: 16792676 [TBL] [Abstract][Full Text] [Related]
38. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Schmitt A; Jouault H; Guichard J; Wendling F; Drouin A; Cramer EM Blood; 2000 Aug; 96(4):1342-7. PubMed ID: 10942376 [TBL] [Abstract][Full Text] [Related]
39. High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes. Tang G; Wang SA; Menon M; Dresser K; Woda BA; Hao S Leuk Res; 2011 Jun; 35(6):766-70. PubMed ID: 21367453 [TBL] [Abstract][Full Text] [Related]
40. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. Rameshwar P; Denny TN; Stein D; Gascón P J Immunol; 1994 Sep; 153(6):2819-30. PubMed ID: 7521370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]